Accelerated progression of multiple myeloma during anti-CD20 (Rituximab) therapy

被引：14

作者：

Korte, W

Jost, C

Cogliatti, S

Hess, U

Cerny, T ^{[1
]}

机构：

[1] Kantonsspital, Div Med Oncol, CH-9007 St Gallen, Switzerland

[2] Kantonsspital, Inst Clin Chem & Haematol, CH-9007 St Gallen, Switzerland

[3] Kantonsspital, Inst Pathol, CH-9007 St Gallen, Switzerland

来源：

ANNALS OF ONCOLOGY | 1999年 / 10卷 / 10期

关键词：

CD20; IL-6; monitoring; multiple myeloma;

D O I：

10.1023/A:1008310819049

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：1249 / 1250

页数：2

共 50 条

[41] Patients with CD45 negative multiple myeloma receiving high-dose therapy have it shorter survival than those with CD45 positive multiple myeloma [J].

Moreau, P ;

Robillard, N ;

Avet-Loiseau, H ;

Pineau, D ;

Morineau, N ;

Milpied, N ;

Harousseau, JL ;

Bataille, R .

HAEMATOLOGICA, 2004, 89 (05) :547-551

[42] Amyloid arthropathy associated with multiple myeloma: polyarthritis without synovial infiltration of CD20+or CD38+cells [J].

Pessler, Frank ;

Ogdie, Alexis R. ;

Mayer, Christian T. ;

Kretzschmar, Warren W. ;

Dai, Lie ;

Elsaman, Ahmed M. ;

Einhorn, Eugene ;

Krenn, Veit ;

Schumacher, H. Ralph .

AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2014, 21 (01) :28-34

[43] Rupture of an extended mycotic aneurysm of the descending thoracic aorta in a multiple myeloma patient undergoing anti-myeloma therapy [J].

Marumoto, Akira ;

Iwata, Keiji .

GENERAL THORACIC AND CARDIOVASCULAR SURGERY, 2016, 64 (03) :163-166

[44] Rupture of an extended mycotic aneurysm of the descending thoracic aorta in a multiple myeloma patient undergoing anti-myeloma therapy [J].

Akira Marumoto ;

Keiji Iwata .

General Thoracic and Cardiovascular Surgery, 2016, 64 :163-166

[45] Infection Risk in Patients with Multiple Myeloma during the Era of Monoclonal Antibody Therapy [J].

Hoffman, Stephanie ;

Kandarpa, Malathi ;

Ye, Jing Christine .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 :S256-S257

[46] Emerging roles of endoglin/CD105 and angiogenic cytokines for disease development and progression in multiple myeloma patients [J].

Pappa, C. A. ;

Alexandrakis, M. G. ;

Boula, A. ;

Psarakis, F. E. ;

Kolovou, A. ;

Bantouna, V. ;

Stavroulaki, E. ;

Tsirakis, G. .

HEMATOLOGICAL ONCOLOGY, 2013, 31 (04) :201-205

[47] Pharmacy considerations: Use of anti-CD38 monoclonal antibodies in relapsed and/or refractory multiple myeloma [J].

Shah, Bhavesh ;

Gray, Joy ;

Abraham, Ivo ;

Chang, Melody .

JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (01) :170-182

[48] Implications for the monitoring of patients with multiple myeloma undergoing treatment with the anti-CD38 monoclonal daratumumab [J].

Thirkettle, Sally ;

Russell, Joanne ;

Wilson, Sarah ;

Ganijee, Tasneem ;

Kulkarni, Samar ;

Cavet, Jim ;

Monaghan, Phillip J. .

ANNALS OF CLINICAL BIOCHEMISTRY, 2020, 57 (02) :178-181

[49] BCMA-CAR Therapy for Multiple Myeloma in NOG Mice Prevents the Progression of Anemia and Bone Lesions [J].

Uchibori, Ryosuke ;

Ohmine, Ken ;

Teruya, Takeshi ;

Mineno, Junichi ;

Ozawa, Keiya .

HUMAN GENE THERAPY, 2025, 36 (11-12) :902-913

[50] Expression of CD19 and CD20 in plasma cells are significantly different between Han and Uygur multiple myeloma patients [J].

Cui, Yanjie ;

Zhang, Fengbo ;

Jiang, Ming ;

Pang, Nannan ;

Li, Zhi Wei ;

Zhu, Yuejie ;

Qu, Jianhua ;

Ding, Jianbing .

INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (07) :13041-13046

← 1 2 3 4 5 →